

EUROPEAN DRUG UTILISATION RESEARCH GROUP CONFERENCE 2020

Medicines: benefits and burdens



EuroDURG 2020 PROGRAMME BOOK



4 - 7 March 2020 | TIK Congress Centre
University of Szeged, Szeged, Hungary

 EuroDURG



 ispe

International Society
for Pharmacoepidemiology



Sponsored by:



International Society
for Pharmacoepidemiology



Dear friends and colleagues,

On behalf of the Scientific and Local Organising Committees we extend a warm welcome to Szeged, Hungary for the EuroDURG Scientific Meeting. Our conference theme is **Medicines: benefits and burdens** and we will be exploring the policy and practice response to current and evolving therapies.

The European Branch of the ISPE Special Interest Group for Drug Utilisation Research has designed an attractive, interactive educational and scientific programme reaching out to our networks both in Europe and internationally. We start with a half day of educational sessions, building on our successful summer school in June 2019, followed by a dynamic range of plenary sessions on: multimorbidity and the evolving challenge of polypharmacy; innovative medicines; emerging data capabilities and antimicrobial resistance – a One Health Approach. These will be interspersed with workshops, seminars, poster walks and thematic sessions to allow our community to engage, develop and test our evolving DUR trajectory to improve the real world use of medicines.

We hope you will join us in lively discussions throughout the meeting. Our tradition has been to combine great scientific content with social events to support networking, meeting new colleagues / old friends and experience a bit of the local country culture.



Marion Bennie
*Chair, Scientific Organising
Committee*



Ria Benkő
*Chair, Local Organising
Committee*

LOCAL ORGANIZING COMMITTEE

Ria Benkő (Chair)
Marion Bennie
Gabriella Bodó
Péter Doró
Monique Elseviers
Zsófia Engi
Githa Fungie Galistiani
Mária Matuz
Tanja Mueller
Krisztina Schváb
Gyöngyvér Soós

SCIENTIFIC COMMITTEE

Marion Bennie (Chair)
Anna Birna Almarsdottir
Ria Benko
Judit Bidló
Monique Elseviers
Brian Godman
Balázs Hankó
Suzanne Rose Hill
Ramune Jacobsen
Tanja Mueller
Paraskevi Voula Papaioannidou
Elisabetta Poluzzi
Gabriel Sanfelix-Gimeno
Gisbert Selke
Gyöngyvér Soós
Douglas Steinke
Katja Taxis
Sabine Vogler
Björn Wettermark

ADVISORY BOARD

☞ **Central/Eastern Europe**

Irina Cazacu
Jolanta Gulbinovic
Katarina Gvozdanović
Ivana Ivanova
Nikica Mirosevic Skvrce
Martin Wawruch
Eva Zimcikova

☞ **Africa**

Johanita Burger

☞ **South America**

Claudia Osorio de Castro
Luciane Cruz Lopez

☞ **Australia**

Frank May
Lisa Pont

☞ **Asia**

Jason C. Hsu

☞ **USA**

Veronika Wirtz

☞ **North America** Carlotta

Lunghi
Ingrid Sketris

☞ **Middle East**

Saleh Aljadeeah

The chief patron of the EuroDURG 2020 conference is:

Prof. Dr. László Rovó
Rector of the University of Szeged

WEDNESDAY 4 MARCH		THURSDAY 5 MARCH		FRIDAY 6 MARCH		SATURDAY 7 MARCH			
		SCIENTIFIC PROGRAM PART I		SCIENTIFIC PROGRAM PART III		SCIENTIFIC PROGRAM PART V			
09.00-10.30		WELCOME PLENARY 1: Multi-morbidity and the evolving challenge of polypharmacy Congress Hall		F-TS5 Cancer & biologicals Lecture Hall	F-TS6 Elderly & polypharmacy Congress Hall	F-TS7 Implement. intervention Lecture Room II	S-TS12 Rerewarding field research Lecture Hall	S-TS13 Pregnancy & paediatrics Lecture Room II	S-TS14 Deprescribing Congress Hall
10.30-11.00		Coffee break		Coffee break		Coffee break			
11.00-12.30		T-TS1 DUR & safety Lecture Room II	T-SY1 Cross-national comparison Lecture Hall	T-TS2 Medication adherence Congress Hall	F-SY2 Policies on deprescribing Lecture Hall	F-TS8 Antimicrobial stewardship interventions Congress Hall	PLENARY 4: Combating antibacterial resistance – a One Health approach CLOSING REMARKS Congress Hall		
12.30-13.30		Lunch		Lunch		Lunch			
		SCIENTIFIC PROGRAM PART II		SCIENTIFIC PROGRAM PART IV					
13.30-14.30		PLENARY 2: Innovative medicines – opportunities and challenges Congress Hall		PLENARY 3: Emerging capabilities to generate medicines intelligence data at scale Congress Hall					
14.30-15.30		W-ES1 Statistics Basic level Seminar Room III	W-ES2 Methods: Basic level Lecture Room I	W-ES3 Adherence (applied) Lecture Room II	POSTER SESSION 1		Legend ES: educational session SY: symposium TS: thematic session including a key lecture (30 mins) and 4 oral abstract presentations (4x15 mins) WS: workshop		
15.30-16.00		Coffee break		Coffee break		POSTER SESSION 2			
16.00-17.30		W-ES4 Statistics: Advanced level Seminar Room III	W-ES5 Methods: Advanced level Lecture Room I	W-ES6 Policy application of DUR Lecture Room II	T-TS3 Challenges for drug and health policy Congress Hall	T-TS4 Psychotropic drug use Lecture Room II	F-TS9 Evolving data streams Lecture Room II	F-TS10 Opioids Congress Hall	F-TS11 CVD and diabetes Lecture Room II
		Welcome Reception 18:00 Rector's Office		EuroDURG General Assembly (17:30-18:30)		EuroDURG party with buffet 19:30 Tisza River café			

EURODURG 2020 CONFERENCE
EUROPEAN DRUG UTILISATION
RESEARCH GROUP CONFERENCE
March 4–7, 2020 Szeged, Hungary



European Drug Utilisation Research Group Conference 2020 Szeged, Hungary

TABLE OF CONTENTS

PROGRAM: WEDNESDAY 4th MARCH..... 5
PROGRAM: THURSDAY 5th MARCH 7
PROGRAM: FRIDAY 6th MARCH..... 11
PROGRAM: SATURDAY 7th MARCH 16
SOCIAL PROGRAM 18
CONFERENCE & EVENT LOCATION AND FACILITIES 20
LIST OF POSTER ABSTRACTS..... 22
NOTES 29

PROGRAM: WEDNESDAY 4th MARCH

14:30-15:30 Seminar Room III	EDUCATIONAL SESSION W-ES1 <i>Basic statistical methods – Presenting, visualising and interpreting drug utilisation data using descriptive statistical methods</i>
	CHAIR: Marion Bennie
AIM	To illustrate how DU data can be presented, visualized and interpreted using descriptive statistical methods
TARGET AUDIENCE	Beginning researchers in the field of DUR with little experience of statistical methods.
SPEAKER 1	Maria Matuz , University of Szeged, Hungary
SPEAKER 2	Tanja Mueller , University of Strathclyde, Glasgow, UK

14:30-15:30 Lecture Room I	EDUCATIONAL SESSION W-ES2 <i>Basic methodology – Classification systems and measurement units in Drug Utilisation Research with a focus on the ATC-DDD system</i>
	CHAIR: Katja Taxis
AIM	To practice opportunities and pitfalls in using different classification systems and measurement units, with a special emphasize on ATC-DDD.
TARGET AUDIENCE	Beginning researchers in the field of DUR with little/no experience in using classification systems like ATC/DDD.
SPEAKER	Hege Salvesen-Blix , WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway

14:30-15:30 Lecture Room II	EDUCATIONAL SESSION W-ES3 <i>Applied adherence – assessment methods and interventions</i>
	CHAIR: Monique Elseviers
AIM	To present different (novel) methods to assess adherence and present an overview of interventions which have shown to improve adherence.
TARGET AUDIENCE	DUR researchers at all levels interested in methods and interventions on adherence.
SPEAKER 1	Gabriel Sanf�lix-Gimeno , Centre for Public Health Research, Valencia, Spain
SPEAKER 2	Bernard Vrijens , University of Li�ge, Belgium

16:00-17:30 Seminar Room III	EDUCATIONAL SESSION W-ES4 <i>Advanced statistical methods – Temporal analyses</i>
	CHAIR: Monique Elseviers
AIMS	Participants will have knowledge of current methods for analysing temporal data in a drug utilization research setting. Practical methods will be demonstrated on suitable examples and using widely available tools, providing participants with the ability to start pursuing their own analyses.
TARGET AUDIENCE	Research students and professionals with a need to analyse the effects of interventions on the patient level of the community level, and with some familiarity with both descriptive and inferential statistics.
SPEAKER 1	Yared Santa-Ana-Téllez , Centre for Public Health Research, Valencia, Spain
SPEAKER 2	Peter Mol , Dutch Medicines Evaluation Board, Utrecht, Netherlands

16:00-17:30 Lecture Room I	EDUCATIONAL SESSION W-ES5 <i>Advanced methodology – The added value of doing mixed-methods research</i>
	CHAIR: Katja Taxis
AIMS	To address the value of mixed methods research and discuss how to include the patients' perspective in Drug Utilisation Research
TARGET AUDIENCE	DUR researcher at different levels with limited experience in using mixed methods (mix of quantitative and qualitative methods).
SPEAKER 1	Katja Taxis , University of Groningen, Netherlands
SPEAKER 2	Lisa Pont , University of Technology Sydney, Australia
SPEAKER 3	Ramune Jacobsen , University of Copenhagen, Denmark

16:00-17:30 Lecture Room II	EDUCATIONAL SESSION W-ES6 <i>Policy applications of drug utilization research</i>
	CHAIR: Marion Bennie
AIM	To give an overview on how DUR may help policymakers in promoting rational use of drugs.
TARGET AUDIENCE	DUR researchers / Policy advisors at different levels interested in how DUR can shape and support policy makers.
SPEAKER 1	Marion Bennie , University of Strathclyde, Glasgow, Scotland
SPEAKER 2	Brian Godman , University of Strathclyde, UK / Karolinska Institutet, Sweden

PROGRAM: THURSDAY 5th MARCH

SCIENTIFIC PROGRAM PART I

9:00-10:30	WELCOME CEREMONY	
Congress Hall	CHAIR: Marion Bennie, UK	CHAIR: Ria Benkő, Hungary
SPEAKERS	István Zupkó – Dean, Faculty of Pharmacy, University of Szeged Marion Bennie – Chair of EuroDURG Gyöngyvér Soós – DUR pioneer in Hungary	
	PLENARY 1	
	<i>Multi-morbidity and the evolving challenge of polypharmacy</i>	
	CHAIR: Sabine Vogler	CHAIR: Gyöngyvér Soós
AIMS	To present current developments around the challenge of multimorbidity and addressing polypharmacy with possible solutions.	
SPEAKER 1	Attila Horváth-Sziklai , Director of the Hungarian Chamber of Pharmacists; on behalf of the Pharmaceutical Group of the European Community (PGEU) <i>Where does Europe go? Challenges and policy responses to multimorbidity</i>	
SPEAKER 2	Professor Bruce Guthrie , Professor of General Practice, University of Edinburgh; Chair of guideline development group for the NICE Multimorbidity Guideline <i>Improving the life of elderly people living with multimorbidity – how to deal with polypharmacy in practice</i>	

11:00-12:30	THEMATIC SESSION T-TS1	
Lecture Room II	<i>The role of drug utilisation data in evaluating safety of drug use</i>	
	CHAIR: Anna Birna Almarsdóttir	CHAIR: Emanuel Raschi
AIMS	To map the potential application of DU data and relevant methods in drug/patient safety studies.	
SPEAKER	Emanuel Raschi , University of Bologna, Italy <i>Signal detection of ADRs by using DU data</i>	
Oral abstract presentation 1	Ellen van Loon , University of Groningen & SIR Institute for Pharmacy Practice and Policy, The Netherlands <i>Nature, frequency and relevance of prescription modification in Dutch community pharmacies</i> [#156]	
Oral abstract presentation 2	Sieta de Vries , Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands <i>Sex differences in reported adverse drug reactions are primarily seen in the first weeks after metformin initiation</i> [#87]	
Oral abstract presentation 3	Vivien Tóth , Department of Clinical Pharmacy, University of Szeged & Albert Szent Györgyi Medical Center, Central Pharmacy, University of Szeged <i>Can we trust in all patient reported drug allergies? Questionnaire based survey</i> [#141]	
Oral abstract presentation 4	Lorena Rocha Ayres , Federal University of Espírito Santo <i>Medication reconciliation at hospital admission and discharge in a cardiology unit: a pilot study</i> [#128]	

11:00-12:30 Congress Hall	THEMATIC SESSION T-TS2 <i>Improving the accuracy of medication adherence assessment</i>	
	CHAIR: Gabriel Sanf�elix-Gimeno	CHAIR: Petra Denig
AIMS	To explore key aspects of medication exposure assessment using electronic databases, with focus on the different aspects of exposure assessment that are relevant for measuring exposure as use over time or as adherence to therapy from a clinical perspective.	
SPEAKER	Dr Helga Gardarsdottir , Utrecht University, Netherlands <i>Medication exposure assessment using electronic databases</i>	
Oral abstract presentation 1	Tanja Mueller , University of Strathclyde, Glasgow, UK <i>Real-world evaluation of the impact of statin intensity on adherence, persistence and discontinuing of statin therapy: evidence from the Scottish population [#18]</i>	
Oral abstract presentation 2	Sofa Alfian , University of Groningen, Groningen Research Institute of Pharmacy, Unit Pharmacotherapy, -Epidemiology & -Economics, Groningen, The Netherlands <i>Predictors of different types of non-adherence to antihypertensive or antihyperlipidemic drugs among patients with diabetes: a multicentre study in Indonesia [#170]</i>	
Oral abstract presentation 3	Martin Wawruch , Institute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University <i>Non-persistence with statin treatment in patients following an ischaemic stroke [#6]</i>	
Oral abstract presentation 4	Kudret Cem �zdemir , University of Copenhagen <i>Asthma medicine compliance determinants among 20,157 individuals from the general population [#57]</i>	

11:00-12:30 Lecture Hall	SYMPOSIUM T-SY1 <i>Challenges for cross-national comparison research</i>	
	CHAIR: Claudia Osorio de Castro	CHAIR: Monique Elseviers
AIMS	What are the opportunities and limitations to perform CNC studies anno 2020?	
SPEAKER 1	Professor Thomas MacDonald , Professor of Clinical Pharmacology, University of Dundee; Deputy Chair ENCePP (European Network of Centres for Pharmacoepidemiology and Pharmacovigilance) <i>Challenges for cross-national comparison research: opportunities in the European region</i>	
SPEAKER 2	Professor Luciane Lu Lopes , University of Sorocaba, Brazil <i>Limitations to perform CNC studies: the example of Latin America</i>	
DISCUSSION ROUND		
<ul style="list-style-type: none"> • Announcement of the publication of the CNC guidelines • Presentation of the Glasgow Declaration on 'Increasing Access to Drug Utilisation Data' and possible routes of dissemination 		

SCIENTIFIC PROGRAM PART II

13:30-14:30 Congress Hall	PLENARY 2 <i>Innovative medicines – opportunities and challenges</i>	
	CHAIR: Marion Bennie	CHAIR: Katja Taxis
AIMS	To understand the range and types of innovative medicines now entering the healthcare system and the challenges / opportunities this provides to drug utilization researchers (DUR) to engage collaboratively at scale, supporting evidence generation for healthcare system policy and practice.	
SPEAKER 1	Dr Mariângela Batista Galvão Simão , Assistant Director General – Access to Medicines and Health Products, World Health Organisation <i>Innovative Medicines – the WHO approach to supporting access to innovative medicines</i>	
SPEAKER 2	Judith Bidlo , National Health Insurance Fund of Hungary <i>Policy adoption across borders – Hungarian national speaker from an HTA perspective</i>	

14:30-15:30	POSTER SESSION 1 <i>For details see 'LIST OF POSTER ABSTRACTS'</i>
ADHERENCE	Posters AD1 to AD9
ANTIMICROBIALS 1	Posters AB1 to AB11
CANCER/BIOLOGICALS + MENTAL HEALTH	Posters CB1 to CB6 Posters MH1 to MH6
CARDIOVASCULAR/DIABETES	Posters CD1 to CD8
DRUG/HEALTH POLICY 1	Posters DH1 to DH12
ELDERLY 1	Posters EL1 to EL12
SAFETY 1	Posters SF1 to SF8

16:00-17:30 Lecture Hall	WORKSHOP T-WS1 <i>Medicines use in old age: Drivers of polypharmacy and quantification of the problem</i>	
	CHAIR: Monique Elseviers	CHAIR: Katja Taxis
AIMS	<ul style="list-style-type: none"> • To obtain more insight into the drivers of polypharmacy • to share research methods to quantify the problem of inappropriate polypharmacy. 	
INTRODUCTION SPEAKER	Professor Bruce Guthrie , Professor of General Practice, University of Edinburgh; Chair of guideline development group for the NICE Multimorbidity Guideline <i>Polypharmacy and (potential) inappropriate medicine use as indicators of the quality of prescribing in old age</i>	
DISCUSSION ROUND	<i>What are the drivers of polypharmacy? What is appropriate/inappropriate polypharmacy? How to quantify inappropriate polypharmacy?</i>	
POSTER WALK	Participants visit posters presenting the results of the other discussion groups	
SUMMARY	<i>How to quantify inappropriate polypharmacy for clinical practice in an individual patient, quality of prescribing as evaluation tool for prescribers and indicator of quality of care in a nursing home</i>	

16:00-17:30 Congress Hall	THEMATIC SESSION T-TS3 <i>Challenges for Drug and Health Policy</i>	
	CHAIR: Gisbert Selke	CHAIR: Sabine Vogler
AIMS	To describe potential ways forward to ensure medium- to long-term adequate access to drugs.	
SPEAKER	Professor Aukje Mantel-Teeuwisse , Utrecht University, Netherlands; Managing Director of WHO Collaborating Centre of Pharmaceutical Policy and Regulation <i>The cost of new drugs vs. safe and secure procurement of established medicines: a precarious balance for social health care systems</i>	
Oral abstract presentation 1	Sieta de Vries , Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands <i>Sex proportionality in pre-clinical and clinical trials evaluated in the dossiers supporting market approval</i> [#88]	
Oral abstract presentation 2	Karen Gronkowski , Information Services Division, NHS National Services Scotland <i>The impact of regulatory guidance on valproate prescribing and harm reduction for females of childbearing potential in NHS Scotland</i> [#35]	
Oral abstract presentation 3	Claudia Garcia Serpa Osorio-de-Castro , Sergio Arouca National School of Public Health, Oswaldo Cruz Foundation <i>Serious adverse events with high-cost drugs accessed through litigation in Brazil</i> [#2]	
Oral abstract presentation 4	Sabine Vogler , WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG / Austrian National Public Health Institute) <i>Can cross-country collaborations improve access to medicines?</i> [#149]	

16:00-17:30 Lecture Room II	THEMATIC SESSION T-TS4 <i>Psychotropic drug use</i>	
	CHAIR: Björn Wettermark	CHAIR: Elisabetta Poluzzi
AIMS	To give an overview of the current knowledge (from published Drug Utilisation studies) on trends in utilization of different psychotropic drugs in Europe and current research in the field.	
SPEAKER	Dr Mikael Hoffmann , Swedish Network for Pharmacoepidemiology (NEPI) <i>Opportunities and challenges in psychotropic drug utilisation studies</i>	
Oral abstract presentation 1	Wael Khawagi , Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester <i>Using an eDelphi consensus technique to develop mental health related indicators to assess prescribing safety</i> [#26]	
Oral abstract presentation 2	Jonas Kindstedt , Umeå University <i>Psychotropic drug use among elderly Swedish people with dementia – a study based on national registries</i> [#31]	
Oral abstract presentation 3	Lucas Morin , Karolinska Institutet <i>Multi-dose drug dispensing and longitudinal changes in psychotropic prescribing patterns among older adults: national matched cohort study</i> [#164]	
Oral abstract presentation 4	Svetlana Skurtveit , Norwegian Institute of Public Health <i>Incidence of diagnosed paediatric anxiety disorders and use of prescription drugs: a nation-wide registry study</i> [#121]	

PROGRAM: FRIDAY 6th MARCH

SCIENTIFIC PROGRAMME PART III

9:00-10:30 Lecture Hall	THEMATIC SESSION F-TS5 <i>Cancer & biologicals</i>	
	CHAIR: Brian Godman	CHAIR: Amanj Kurdi
AIMS	To appraise ongoing activities among European countries to improve the use of available resources to better manage patients with cancer given competing pressures. This includes reviewing ongoing activities across Europe at key stages of the lifecycle, with a special emphasis on drug utilization studies.	
SPEAKER	Professor Brian Godman , University of Strathclyde, UK; Karolinska Institutet, Sweden; Sefako Makgatho Health Sciences University, South Africa <i>Initiatives across countries to optimise available resources for patients with cancer including greater use of bio-similars and real world data</i>	
Oral abstract presentation 1	Ruth Norris , School of Pharmacy, Newcastle University <i>Are there socio-economic inequalities in utilisation of novel cancer therapies? A systematic review</i> [#148]	
Oral abstract presentation 2	Sabine Vogler , WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG / Austrian National Public Health Institute) <i>Cross-country comparison of policies for biosimilar medicines</i> [#150]	
Oral abstract presentation 3	Andrea Spini , Service de Pharmacologie Médicale, Université de Bordeaux, CHU de Bordeaux, Bordeaux, France <i>Linking regional administrative healthcare data with the pathology registry of the University Hospital of Siena (Italy) to describe treatment patterns of patients with non-small-cell lung cancer</i> [#144]	
Oral abstract presentation 4	Meera Varma , University of Copenhagen, Faculty of Health and Medical Sciences, Department of Pharmacy, Social and Clinical Pharmacy Research Group <i>Biosimilar, so it looks alike, but what does it mean? – A qualitative study of patients' perceptions of biosimilars in Denmark</i> [#61]	

9:00-10:30 Congress Hall	THEMATIC SESSION F-TS6 <i>Elderly patients – the clinical perspective on polypharmacy</i>	
	CHAIR: Katja Taxis	CHAIR: Tinne Dilles
AIM	To discuss the challenges of managing polypharmacy in practice.	
SPEAKER	Katharina Schmidt-Mende , practicing GP from Stockholm, Sweden <i>It's just one piece of the puzzle – A GP's experiences regarding inappropriate prescribing in frail older people</i>	
Oral abstract presentation 1	Hege Salvesen Blix , Norwegian Institute of Public Health <i>Time trends in the use of proton-pump inhibitors in the elderly in Norway, including co-medication with NSAIDs or low-dose ASA</i> [#168]	
Oral abstract presentation 2	Carina Lundby , Hospital Pharmacy Funen, Odense University Hospital <i>Use of medication among nursing home residents: A Danish drug utilisation study</i> [#27]	
Oral abstract presentation 3	Maarten Wauters , Ghent University, Gent, Belgium <i>Linking anti-cholinergic exposure to outcome in nursing home residents: associations with anticholinergic symptoms, alertness and mortality</i> [#95]	
Oral abstract presentation 4	Irina Dumitrescu , University of Antwerp <i>High-risk medication in community care</i> [#10]	

9:00-10:30 Lecture Room II	THEMATIC SESSION F-TS7 <i>Implementation of interventions</i>	
	CHAIR: Suzanne Rose Hill	CHAIR: Tanja Mueller
AIMS	To review and examine the implementation of interventions with the potential to improve medicines management.	
SPEAKER	Professor Margaret Watson , University of Strathclyde, Glasgow, UK <i>The Art and the Science of Implementation</i>	
Oral abstract presentation 1	Carolina Tisnado-Garland , Université Laval <i>Impact of a new pharmaceutical care model on polypharmacy in long term care facilities in Canada</i> [#157]	
Oral abstract presentation 2	Sean MacBride-Stewart , University of Dundee, Scotland <i>Electronic prescription data to improve primary care prescribing (EPIPP)</i> [#82]	
DISCUSSION ROUND: How to implement interventions and how to evaluate the impact of these interventions.		

11:00-12:30 Congress Hall	THEMATIC SESSION F-TS8 <i>Antimicrobial stewardship interventions</i>	
	CHAIR: Voula Papaioannidou	CHAIR: Ria Benkő
AIMS	To give insight into Drug Utilisation Research (DUR) studies across the globe on effective interventions/antibiotic stewardship programmes, and DUR studies which identified irrational prescribing of antibacterial drugs. This session is complementary to <i>Plenary 4</i> .	
SPEAKER	Dr Esmita Charani , Imperial College London, UK <i>Policies aiming at confining antibacterial resistance</i>	
Oral abstract presentation 1	Lucas Pereira , School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo <i>Antimicrobial consumption at a high complexity hospital in Brazil: utilisation profile from different wards</i> [#154]	
Oral abstract presentation 2	Githa Fungie Galistiani , Department of Clinical Pharmacy, Faculty of Pharmacy, University of Szeged <i>Variations in antibiotic prescribing for children – Hungary, 2017</i> [#132]	
Oral abstract presentation 3	Brian Godman , Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde <i>The impact of law enforcement on the dispensing of antibiotics without prescription in Saudi Arabia: findings and implications</i> [#14]	
Oral abstract presentation 4	Brian Godman , Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde <i>Eight-year study of antibiotic utilisation in the Republic of Srpska (2010-2017 years); findings and implications</i> [#51]	

11:00-12:30 Lecture Room II	THEMATIC SESSION F-TS9 <i>Evolving data streams</i>	
	CHAIR: Marion Bennie	CHAIR: Ramune Jacobsen
AIMS	To explore how evolving data streams can be/are being used to explore and understand better the impact of medicines at both an individual level to support clinical care and at a population level to derive the impact and value of medicines.	
SPEAKER	Dr Natasja Kingod , Steno Diabetes Centre Copenhagen, Denmark <i>How can new data streams add value to current data assets used to understand the effect/side effects of medicines?</i>	
Oral abstract presentation 1	Linda van Eikenhorst , University of Groningen, Groningen Research Institute of Pharmacy, PharmacoTherapy, -Epidemiology & -Economics, Groningen, The Netherlands <i>Patients address more than medication related problems with their pharmacist – A video observation study of clinical medication reviews [#127]</i>	
Oral abstract presentation 2	Ina Vierø Rinder , University of Copenhagen, Faculty of Health and Medical Sciences, Department of Pharmacy, Social and Clinical Pharmacy Research Group <i>The Danish translation of the Medicines-Related Quality of Life scale from the patient perspective [#62]</i>	
Oral abstract presentation 3	Karin Hek , Nivel, Netherlands Institute for Health Services Research <i>Monitoring burden and benefits of medication for overactive bladder: combining electronic health records and patient reported outcomes [#33]</i>	
Oral abstract presentation 4	Emma Dunlop , University of Strathclyde <i>What do prostate cancer patients and clinicians want from an app and a dashboard to collect Patient Reported Outcomes (PROMs) as part of routine care? [#15]</i>	

11:00-12:30 Lecture Hall	SYMPOSIUM F-SY2 <i>Policies on deprescribing – an international view</i>	
	CHAIR: Katja Taxis	CHAIR: Lisa Pont
AIMS	<ul style="list-style-type: none"> to provide an overview of the policies that have been introduced to implement deprescribing in practice illustrate the challenges to implement deprescribing in practice, taking into account the different stakeholders – especially prescribers and patients. 	
PANEL MEMBER 1	Dr Anton Pottegård , Associate Professor, University of Southern Denmark, Odense <i>Introduction to the concept of deprescribing and highlighting challenges ahead.</i>	
PANEL MEMBER 2	Carina Lundby , University of Southern Denmark, Odense <i>Highlighting barriers to and enablers of deprescribing from the perspective of health care professionals (physicians, pharmacists and nurses) and patients and their relatives/carers.</i>	
PANEL MEMBER 3	Wade Thompson , University of Southern Denmark, Odense	
PANEL MEMBER 4	Professor Petra Denig , University of Groningen, Netherlands	
PANEL MEMBER 5	Dr Lisa Pont , University of Technology Sydney, Australia	

12:30-13:30	EARLY-CAREER RESEARCHER EVENT	
Lecture Hall	CHAIR: Tanja Mueller	CHAIR: Ramune Jacobsen
AIMS	To initiate networking activities for early-career researcher in drug utilisation.	
DESCRIPTION: This will be a short, informal session over lunch, while enjoying food. It will start with informal networking and continue with discussions in smaller groups on issues of network building and funding, as well as publishing, opportunities and strategies.		

SCIENTIFIC PROGRAMME PART IV

13:30-14:30	PLENARY 3 <i>Emerging capabilities to generate medicines intelligence data at scale</i>	
Congress Hall	CHAIR: Anna Birna Almarsdóttir	CHAIR: Katja Taxis
AIMS	To provide insight into the emerging technologies that will enable new data capture at scale, which opportunities these will offer to drug utilization research, and which challenges they will bring from a researcher and citizen perspective.	
SPEAKER 1	Dr Miklós Szócska , Director of the Health Services Management Training Centre, Semmelweis University, Hungary <i>Opportunities offered by machine learning/artificial intelligence approaches applied to routine health and care data</i>	
SPEAKER 2	Dr Natasja Kingod , Steno Diabetes Centre Copenhagen, Denmark <i>Data shared by patients on social media – a new way to learn about medicines use</i>	

14:30-15:30	POSTER SESSION 2 <i>For details see 'LIST OF POSTER ABSTRACTS'</i>
ANTIMICROBIALS 2	Posters AB12 to AB21
DRUG/HEALTH POLICY 2	Posters DH13 to DH20
ELDERLY 2	Posters EL13 to EL22
ELDERLY 3	Posters EL23 to EL31
INTERVENTION/IMPLEMENTATION	Posters II1 to II9
PATIENT VOICE	Posters PV1 to PV12
SAFETY	Posters SF9 to SF14

16:00-17:30	WORKSHOP F-WS2 <i>Drug Utilisation Research as a tool in the introduction of new medicines</i>	
Lecture Hall	CHAIR: Björn Wettermark	CHAIR: Marion Bennie
AIMS	To explore how drug utilization studies can contribute to improve lifecycle management of new innovations in healthcare. There will be a specific focus on medicines, but the methods may be applicable also to other technologies.	
SPEAKER 1	Professor Björn Wettermark , University of Uppsala, Sweden <i>What drug utilization studies may be conducted in different phases of the medicine life cycle – introduction to session</i>	
SPEAKER 2	Professor Ylva Böttiger , Linköping University, Sweden <i>Drug marketing strategies in a changing drug market; implications for health care</i>	

16:00-17:30 Congress Hall	THEMATIC SESSION F-TS10 <i>Opioid-use and risk of opioid-related harm</i>	
	CHAIR: Douglas Steinke	CHAIR: Ulf Bergman
AIMS	To explore the current evidence of opioid utilization, risk of opioid-related harm and medication optimization strategies for patients with chronic pain.	
SPEAKER	Dr Li-Chia Chen , University of Manchester, UK <i>Applying drug utilization research to tackle the challenges of optimizing opioid utilization and chronic pain management</i>	
Oral abstract presentation 1	Irina Cazacu , Iuliu Hatieganu University of Medicine and Pharmacy, Department of Pharmacology, Physiology and Pathophysiology, Faculty of Pharmacy <i>Tramadol use in Romania during 2014 – 2018</i> [#65]	
Oral abstract presentation 2	Lotte Rasmussen , Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense <i>Use of tramadol and other opioids following media attention</i> [#173]	
Oral abstract presentation 3	Yvette Weesie , Nivel, Utrecht, The Netherlands <i>Prescriptions of rapid onset fentanyl in Dutch primary care</i> [#133]	
Oral abstract presentation 4	Willemijn Meijer , Nivel, Utrecht, The Netherlands <i>Is opioid prescribing in out-of-hours primary care followed by prescriptions from the patient's own daytime general practitioner?</i> [#69]	

16:00-17:30 Lecture Room II	THEMATIC SESSION F-TS11 <i>Cardiovascular diseases and diabetes</i>	
	CHAIR: Elisabetta Poluzzi	CHAIR: Ramune Jacobsen
AIMS	To define potential approaches to monitor drug utilisation in chronic therapies when new and old medicines coexists.	
SPEAKER	Rosa Gini , Tuscany Health Agency, Italy <i>Trajectory identification in chronic cardiovascular treatment and their role in drug utilization appropriateness assessment</i>	
Oral abstract presentation 1	Indre Treciokiene , Department of Pharmacy, University of Groningen, Netherlands, Pharmacy center, Institute of Biomedical Science, Faculty of Medicine, Vilnius University, Lithuania <i>Trend of antihypertensive medicine use in the Baltic states between 2014 and 2018</i> [#109]	
Oral abstract presentation 2	Kani Khalaf , Unit for Social Epidemiology, Department of Clinical Sciences, Faculty of Medicine, Lund University, Malmö, Sweden <i>Low adherence to statin treatment during the first year after an acute myocardial infarction is associated with increased second year mortality risk – an inverse probability of treatment weighted study on 54,872 patients</i> [#42]	
Oral abstract presentation 3	Sieta de Vries , Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands <i>Sex differences in cardio-metabolic treatment among patients with type 2 diabetes</i> [#89]	
Oral abstract presentation 4	Ippazio Cosimo Antonazzo , Epidemiology Unit, Regional Agency for Healthcare Services of Tuscany, Florence, Italy <i>The first year experience of PCSK9 inhibitors availability in Tuscany: a regional multi-database drug utilisation study</i> [#90]	

PROGRAM: SATURDAY 7th MARCH

SCIENTIFIC PROGRAMME PART V

9:00-10:30 Lecture Hall	THEMATIC SESSION S-TS12 <i>The re-rewarding of primary data collection and field research</i>	
	CHAIR: Claudia Osorio de Castro	CHAIR: Douglas Steinke
AIMS	This session aims to present creative and innovative methodological approaches of field research to counter the limitations of big data and to employ possible sources of information in resource-restricted settings.	
SPEAKER	Professor Monique Elseviers , Universities of Antwerp and Ghent, Belgium <i>Creative methodologies of primary data collection and field research in resource-restricted settings: examples, opportunities and limitations</i>	
Oral abstract presentation 1	Tatiana Luz , Oswaldo Cruz Foundation <i>Individual and contextual determinants of out-of-pocket expenditures on medicines in primary care</i> [#41]	
Oral abstract presentation 2	Stijn Crutzen , Department of Clinical Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands <i>Self-reported causes of hypoglycaemia and problems with self-management of blood-glucose treatment in type 2 diabetes patients: a survey study</i> [#116]	
Oral abstract presentation 3	Peter G.M. Mol , University Medical Center Groningen <i>Demographic and clinical factors that impact importance attached to drug effects: a preference study among type 2 diabetes patients</i> [#159]	
Oral abstract presentation 4	Elyne De Baetselier , University of Antwerp <i>Nurses' role in inter-professional pharmaceutical care in 14 European countries: a qualitative interview study in pharmacists, physicians and nurses</i> [#52]	

9:00-10:30 Lecture Room II	THEMATIC SESSION S-TS13 <i>Drug utilisation in pregnancy and paediatrics</i>	
	CHAIR: Antonio Clavenna	CHAIR: Gabriel Sanfelix-Gimeno
AIMS	To give an overview of hot topics, state-of-the-art methods and recent trends in Drug Utilisation Research (DUR) studies in pregnancy (e.g. anti-epileptics, retinoid acids etc.) and in the paediatric population across Europe and worldwide.	
SPEAKER	Dr Barbara Mostacci , Neurological Science Institute, Bologna, Italy <i>Safety of antiepileptic use in women with childbearing potential: collaboration between clinicians and DURers is needed</i>	
Oral abstract presentation 1	Alessandro Cesare Rosa , Department of Epidemiology, ASL Roma 1, Lazio regional healthservice <i>Use of different types of gonadotropins for infertility treatment: different patterns and time trends in a central Italian region</i> [#11]	
Oral abstract presentation 2	Stuart McTaggart , Information Services Division, NHS National Services Scotland <i>Use and choice of contraception among valproate-treated females aged 14 – 45 years in comparison with the general population in Scotland and the impact of regulatory safety guidance</i> [#34]	
Oral abstract presentation 3	Marte Handal , Norwegian Institute of Public Health <i>In utero opioid exposure and risk of ADHD in childhood: A Scandinavian registry study</i> [#151]	

9:00-10:30	THEMATIC SESSION S-TS14	
Congress Hall	<i>Deprescribing</i>	
	CHAIR: Katja Taxis	CHAIR: Balázs Hanko
AIMS	To give an overview of current research with a focus on deprescribing policies and interventions across Europe.	
DESCRIPTION: This session will comprise short presentations of research projects conducted across Europe.		
Oral abstract presentation 1	Lucas Morin , Karolinska Institutet <i>Don't stop me now? The continuation of statins among newly admitted nursing home residents</i> [#163]	
Oral abstract presentation 2	Carina Lundby , Hospital Pharmacy Funen, Odense University Hospital <i>I simply don't know because I don't know which drugs I get: A qualitative study of perspectives on deprescribing among older adults with limited life expectancy and their relatives</i> [#21]	
Oral abstract presentation 3	Stijn Crutzen , Department of Clinical Pharmacology, University of Groningen; University Medical Center Groningen, Groningen, The Netherlands <i>Attitudes of older patients towards deprescribing in general and regarding diabetes and cardiovascular medication</i> [#119]	
Oral abstract presentation 4	Barbara Roux , INSERM UMR 1248, University of Limoges <i>Attitudes of community-dwelling older adults and caregivers towards deprescribing in French-speaking countries</i> [#28]	
Oral abstract presentation 5	Nina-Kristin Mann , Department of Clinical Pharmacology, School of Medicine, Faculty of Health, Witten/Herdecke University <i>Development of a deprescribing manual for the COFRAIL study, a cluster-randomised controlled trial in primary care</i> [#23]	

11:00-12:30	PLENARY 4	
Congress Hall	<i>Combating antibacterial resistance – a One Health approach</i>	
	CHAIR: Ria Benkő	CHAIR: Marion Bennie
AIMS	<ul style="list-style-type: none"> to provide state-of-the-art data on antimicrobial resistance, antimicrobial use and consequences to provide guidance by demonstrating effective interventions and major barriers. 	
SPEAKER 1	Dr Dominique Monnet , Head of Programme, Antimicrobial Resistance and HAI Programme, European Centre for Disease Prevention and Control (ECDC), Sweden <i>European burden of antimicrobial resistance and its relationship to antimicrobial use</i>	
SPEAKER 2	Dr Esmita Charani , Senior Lead Pharmacist, NIHR Health Protection Research Unit for Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, UK <i>Effective interventions improving and changing care</i>	
	CLOSING CEREMONY	
SPEAKERS	Ria Benkő & Marion Bennie	

SOCIAL PROGRAM

Wednesday 4th March – 6:00 pm.



The Welcome Reception will take place in the Rector's Office of the University of Szeged (Szeged, Dugonics square 13) on Wednesday, 4th March at 6:00 pm. It is a 3-5 minutes walk from the Congress Centre.

All conference delegates are invited to join for welcome drinks & finger food. Attendees must register for the Welcome Reception in advance.

Zoltán Kónya, educational vice rector of the University of Szeged and Sándor Nagy, vice mayor of Szeged will give a welcoming speech in the beautiful main building of the university. You will also be met with stunning piano music played by Anna Rónaszéki, exceptional pharmacy student and gifted pianist.

Friday 6th March – 7:30 pm.


Enjoy a remarkable Networking Dinner on Friday, 6th March at 7.30 pm. The EuroDURG party will take place in the Tisza River Café (Szeged, Felső Tisza-Part), at the exquisite riverside of one of the main attractions of Szeged, the beautiful River Tisza. To get there, we recommend walking along the riverside (it is approximately 30 minutes on foot from the Congress Centre).



The dinner is a great opportunity to relax and get to know your fellow conference delegates. All attendees must register for the dinner in advance. The dress code is smart casual.


You will receive a welcome drink on arrival and there will be no shortage of delicious food either: the self-service buffet filled with tempting dishes will be waiting for you. Throughout the evening, you can listen and dance to fantastic live music so every element of a great party will be at one place. The one thing we still need is you - do not hesitate to come and have an incredible time!

The amazing band that will play during the party is called *Black Five*. You can check out their repertoire here: http://www.blackfive.hu/?page_id=140



CONFERENCE & EVENT LOCATION AND FACILITIES

GETTING HERE



TIK Congress Centre

Address: H-6722 Szeged, Ady square 10.

GPS: [46.247339, 20.141838](https://www.google.com/maps/place/46.247339,20.141838)

You can use the following modes of public transportation in Szeged: bus, trolley, tram, taxi.

If you take a train to Szeged, you can take the tram that stops in front of the station into the city centre. Tickets may be purchased at the kiosk at the exit (about 300 HUF). You can also walk to downtown (about 20 minutes).

You can purchase a ticket for public transportation on board for an extra price. One ride is 450 HUF per person.

The Congress Centre is in a walking distance from all the accommodations (maximum 25-30 minutes):

- **Art Hotel Szeged:** 10 minutes on foot.
- **Hotel Science:** 5 minutes on foot.
- **Hotel Auris:** 10 minutes on foot.
- **Hotel Novotel Szeged:** 22 minutes on foot. You can also use tram No. 4 (You should get off at the 'Vitéz Street' stop that is almost directly at the Congress Centre).
- **Hunguest Hotel Forrás Szeged:** 25 minutes on foot. You can take bus No. 71 or 71A into the city centre (Széchenyi square) which is at a 10 minutes distance from the Congress Centre on foot.

Parking: If you travel by car, you can park your vehicle on the streets. Parking tickets can be purchased from parking meters. There is also a parking garage about 3 minutes from the Congress Centre (Honvéd square 7, entrance on Tisza Lajos krt., GPS: [46.248391, 20.1450093](https://www.google.com/maps/place/46.248391,20.1450093)).

WI-FI AND INTERNET

Everyone will receive their individual login name and password at the Registration Desk. The Congress Centre also has Eduroam Wi-Fi roaming service.

NO SMOKING

Smoking is forbidden in the whole area of the building of the SZTE TIK and within a distance of 5 meters from the entrance of the building, except for the designated place.


Places designated for smoking: in the outer smoking area of the University Café and the bicycle storages located in front of the main entrance of the building, and at two places beyond the 5-meter distance from entrance at Zászló Street.

CLOAKROOM


Cloakroom facilities are available at no cost. The University accepts no responsibility for items left unattended in the cloakroom, or in any other area of the building.

CONFERENCE VENUE FLOOR PLANS

GROUND FLOOR



FIRST FLOOR



LIST OF POSTER ABSTRACTS

	NO.	WALK	TITLE	PRESENTING AUTHOR
ADHERENCE	AD1	T	The influence of quality of life in medication adherence among type 2 diabetes patients [#30]	Olga Horvat
	AD2	T	Geographical and sociodemographic differences in discontinuation with medication for Chronic Obstructive Pulmonary Disease: an innovative multilevel analysis [#45]	Kani Khalaf
	AD3	T	Factors Associated with Primary Non-adherence to Newly Initiated Direct Oral Anticoagulants in Patients with Non-Valvular Atrial Fibrillation [#78]	Alethea Charlton
	AD4	T	Patterns of antipsychotic use in incident users of second-generation long-acting injectable antipsychotics [#93]	Donica Janzen
	AD5	T	Adherence of antidepressant drugs in Catalonia, 2010-2015 [#102]	Lina Fernanda Camacho Arteaga
	AD6	T	Longitudinal trajectories of adherence to direct oral anticoagulants and associated factors in patients with atrial fibrillation in the SIDIAP database (Catalonia) [#161]	Lina María Leguizamó Martínez
	AD7	T	Identifying adherence patterns across multiple medications and their association with health outcomes in older community-dwelling adults with multimorbidity [#176]	Caroline Walsh
	AD8	T	Adherence to the oral antidiabetic therapy with gliptins [#186]	Ilaria Sconza
	AD9	T	Persistence of biologic treatments in patients with inflammatory bowel disease [#201]	Hanga Takacs
ANTIMICROBIALS 1	AB1	T	Antibiotic prophylaxis for the prevention of surgical site infection in low and middle income countries (LMICs): A scoping review [#5]	Amanj Kurdi
	AB2	T	Assessment of antimicrobial use and prescribing practices among paediatric inpatients in Zimbabwe [#17]	Brian Godman
	AB3	T	Antimicrobial Point Prevalence Surveys in two Ghanaian hospitals: opportunities for antimicrobial stewardship [#24]	Brian Godman
	AB4	T	Availability and use of therapeutic interchange policies in managing antimicrobial shortages among South African public sector hospitals; findings and implications [#40]	Brian Godman
	AB5	T	Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications [#54]	Brian Godman
	AB6	T	Knowledge level and attitude assessment of Hungarian and International medical students on antimicrobial use and resistance: a cross-sectional survey [#58]	Márió Gajdács
	AB7	T	Knowledge, attitude and practice of community pharmacists in Hungary regarding appropriate antibiotic use and antimicrobial resistance [#59]	Márió Gajdács
	AB8	T	Co-medication and co-morbidity in Norwegian HIV-positive patients [#74]	Hege Salvesen Blix
	AB9	T	Antibacterial consumption among the elderly in community care in Hungary and Sweden [#77]	Réka Bordás
	AB10	T	People awareness about antibiotic-resistance: a survey conducted in Southern Italy [#124]	Sara Mucherino
	AB11	T	Veterinary drug dispensation in community pharmacies: focusing on anti-infectives [#129]	Zsófia Engi

ANTIMICROBIALS 2	AB12	F	Broad spectrum antibiotics: comparison of prescribing sites in Portugal [#140]	Ana Araújo
	AB13	F	Updates on WHO tools for monitoring and reporting global antibiotic use [#183]	Verica Ivanovska
	AB14	F	Antimicrobial agent choice for outpatient treatment of non severe community acquired pneumonia – Moscow prescribers’ choice and real practice [#184]	Sergey Gatsura
	AB15	F	Comparison of inpatient-care antibiotic consumption patterns in three Hungarian tertiary-care university hospitals [#189]	Gábor Kardos
	AB16	F	Predicting future antibiotic consumption using time-series analysis [#191]	Gábor Kardos
	AB17	F	Treatment and outcome of Clostridium difficile infections: a retrospective study in a tertiary care infectology Unit [#193]	Tomozi László Béla
	AB18	F	Use and self-medication with antibiotics among adults living in a Brazilian Amazon city: a panel of two cross-sectional studies, 2015-2019 [#197]	Luciane Cruz Lopes
	AB19	F	Antibiotic stewardship activities performed by clinical pharmacist: report of two efficacious cases [#199]	Zsuzsanna Haleder
	AB20	F	The trends and patterns of antibiotic consumption in a tertiary care Neurosurgery Department [#202]	Réka Viola
	AB21	F	Commonly isolated pathogens and Antibiotic susceptibility testing in patients with decubitus hospitalized at a tertiary care hospital in Stip [#207]	Verica Ivanovska
CANCER/BIOLOGICALS	CB1	T	Brazilian indigenous population under chemotherapy: A five-year profile [#84]	Claudia Garcia Serpa Osorio-de-Castro
	CB2	T	Real-world safety and effectiveness of systemic treatments against metastatic colorectal cancer: a systematic review [#110]	Haya Yasin
	CB3	T	Inventory of biological and biosimilar medicine data sources in Europe: the European University Hospitals Alliance (EUHA) landscape [#112]	Carla Sans
	CB4	T	A systematic review of cost-effectiveness evidence to support primary endocrine therapy for treating older women with primary breast cancer [#134]	Yubo Wang
	CB5	T	Treatment patterns of patients initiating TNF α inhibitor therapy [#142]	Rosanne Meijboom
	CB6	T	Trends in the use of systemic anti-inflammatory biologics: A Danish nationwide drug utilization study [#206]	Mette Reilev
CARDIOVASCULAR/ DIABETES	CD1	T	Medicines availability among hypertensive patients in primary healthcare facilities in a rural province in South Africa [#72]	Brian Godman
	CD2	T	Temporal and spatial variation in the prescribing of oral anticoagulants in Scotland - a nationwide record linkage study [#79]	Tanja Mueller
	CD3	T	Overview of insulin utilization between 2013 and 2018 [#91]	Péter Doró
	CD4	T	Lipid modifying drug use in Hungary between 2008 and 2018 [#92]	Péter Doró
	CD5	T	Utilization of anticoagulants in Central Europe and the neighbouring countries [#123]	Eva Zimcikova
	CD6	T	The role of pharmacists in assessing the cognitive functions of patients with metabolic syndrome [#136]	Zuzana Mačková
	CD7	T	Barriers and Enablers of Deprescribing Preventive Cardiovascular/ Diabetes Medication: Health Care Professionals’ Perspective [#147]	Petra Denig
	CD8	T	Key factors influencing the prescribing of statins: a qualitative study among physicians working in primary health care facilities in Indonesia [#152]	Sylvi Irawati

DRUG/HEALTH POLICY 1	DH1	T	Public purchases of eculizumab by the Brazilian Ministry of Health: A profile of volumes and expenses from 2007 to 2018 [#3]	Claudia Garcia Serpa Osorio-de-Castro
	DH2	T	Profiling purchase volumes and expenditures with Direct-Acting Antiretrovirals for Hepatitis C by the Brazilian Ministry of Health, 2015-2018 [#4]	Claudia Garcia Serpa Osorio-de-Castro
	DH3	T	Out of Pocket or Out of Control: A Qualitative Analysis of Healthcare Professional Stakeholder Involvement in Pharmaceutical Policy Change in Ireland [#8]	Gary L. O'Brien
	DH4	T	Health Technology Assessment Decisions for Oncology-related technologies in Brazil: an assessment of CONITEC recommendations, 2012-2018 [#22]	Claudia Garcia Serpa Osorio-de-Castro
	DH5	T	Consumer willingness to pay for a hypothetical chikungunya vaccine in Brazil and the implications [#25]	Brian Godman
	DH6	T	Antineoplastic agents for breast cancer in Brazil: Which federal institutions practise best prices? [#39]	Claudia Garcia Serpa Osorio-de-Castro
	DH7	T	National Pharmacovigilance Systems of Portugal and Brazil [#43]	Vera Lucia Edais Pepe
	DH8	T	Market approval of new medicines in Brazil, United States of America and Portugal [#44]	Vera Lucia Edais Pepe
	DH9	T	Neuropsychiatric drug expenditures' trends and drivers in Minas Gerais, Brazil, from 2010 to 2017 [#47]	Tatiana Luz
	DH10	T	Knowledge of prescribed drugs among primary care patients [#48]	Tatiana Luz
	DH11	T	Are the medicines really available in the Brazilian public health system? [#49]	Tatiana Luz
	DH12	T	National Formulary - A tool to support prescription and efficient use of medicines in Portugal [#56]	Maria Madalena Fonseca
DRUG/HEALTH POLICY 2	DH13	F	Medicine shortages and challenges with the procurement process among public sector hospitals in South Africa; findings and implications [#55]	Brian Godman
	DH14	F	A qualitative evaluation of compliance to prescribing guidelines in public health care facilities in Namibia [#70]	Brian Godman
	DH15	F	Presentation of a web-based tool to monitor drug utilization and healthcare consumption in Region Stockholm [#81]	Elin Dahlén
	DH16	F	Dosing patterns of non-vitamin K oral anticoagulants in patients with atrial fibrillation in Valencia Spain [#111]	Yared Santa-Ana-Tellez
	DH17	F	Trend and pattern of proton pump inhibitors use in Portugal [#138]	Ana Araújo
	DH18	F	Comparing drug expenditures in the Scandinavian capitals [#181]	Martin Erik Nyeland
	DH19	F	How many and how fast Latin American regulators approve new cancer drugs previously approved by EMA? [#195]	Carlos E. Durán
	DH20	F	Do Latin American regulators directly recognize new drugs approved by internationally known regulators? [#198]	Carlos E. Durán

ELDERLY 1	EL1	T	Rates, Determinants, and Effects of Implementing Deprescribing in People with Type 2 Diabetes: A Scoping Review Focusing on Cardiometabolic Medication [#1]	Monika Pury Oktora
	EL2	T	High-risk medication in community care: a scoping review [#12]	Irina Dumitrescu
	EL3	T	High-risk medication in community care: a Delphi consensus study [#13]	Irina Dumitrescu
	EL4	T	Cross-cultural adaptation and psychometric validation of the French version of the revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire [#29]	Barbara Roux
	EL5	T	Updating the PRISCUS list of potentially inappropriate medications for the elderly – Asking the right questions to consult the oracle(s) of Delphi [#63]	Nina-Kristin Mann
	EL6	T	Benzodiazepine and other potentially inappropriate medication use among older adult in relation with multimorbidity: a population-based descriptive study from 2000-2016 [#64]	Emmanuelle Gosselin
	EL7	T	Retrospective analysis of inappropriate medication prescription in elderly population in two Italian settings [#75]	Veronica Russo
	EL8	T	Predicting falling by medication use – assessing diagnostic performance of the Drug Burden Index and the list of Fall Risk-Increasing Drugs [#76]	Katja Taxis
	EL9	T	The prevalence of polypharmacy and the use of potentially inappropriate medications: a cross-national study in Five European countries [#83]	Marion Bennie
	EL10	T	Deprescribing antipsychotics in nursing homes [#85]	Charlotte Vermehren
	EL11	T	Prevalence of drug-disease interactions in older patients in primary care – observational register study [#86]	Katharina Schmidt-Mende
	EL12	T	Medication review in elderly at long term care facilities with caregiver qualification [#94]	Dagmar Abelone Dalin
ELDERLY 2	EL13	F	Use of medicines by the elderly in Portugal [#97]	Ana Araujo
	EL14	F	Interventions to deprescribe proton pump inhibitors among patients with no indication for continued treatment [#98]	Alaa Burghle
	EL15	F	Attitudes towards deprescribing in older adults with limited life expectancy: Two systematic reviews [#99]	Alaa Burghle
	EL16	F	Multimorbidity and polypharmacy patterns: systematic association between chronic diseases and dispensed drugs [#101]	Sara Mucherino
	EL17	F	Nursing home residents' thoughts on discussing deprescribing of cardiovascular preventive medications [#106]	Wade Thompson
	EL18	F	Medication review in long-term care facility for blind and visually impaired elderlies [#107]	Charlotte Vermehren
	EL19	F	Comparing polypharmacy in nursing homes and in the community dwelling Elderly in Italy: different patients, tools and methods to monitor risk of drug-drug interactions (DDIs) [#113]	Elisabetta Poluzzi
	EL20	F	Developing an algorithm to identify patients at high risk for hypoglycaemia in community pharmacies [#114]	Stijn Crutzen
	EL21	F	Pharmacovigilance programme in emergencies room (ER) [#115]	Kristopher Amaro Hosey
	EL22	F	Causes of hypoglycemia in type 2 diabetes patients from patients' perspective: a qualitative interview study [#118]	Stijn Crutzen

ELDERLY 3	EL23	F	Polypharmacy in elderly outpatients population in Southern Italy [#125]	Sara Mucherino
	EL24	F	Gender difference analysis in elderly outpatients population in Southern Italy [#126]	Sara Mucherino
	EL25	F	Analgesic Use and Pain Among Older Adults with Intellectual Disabilities: A Cross-Sectional Study [#131]	Maire O'Dwyer
	EL26	F	Polypharmacy in older men and women in Greece [#153]	Paraskevi Papaioannidou
	EL27	F	Can pharmacist-led medication reviews be integrated in a diabetes care program? An exploratory study in Dutch primary care [#166]	Katja Taxis
	EL28	F	Prevalence and predictors of potential drug-drug interactions in an older community-based population [#179]	Veronica Russo
	EL29	F	Towards safe medication use of geriatric patients at care homes: a combined tool for identification of potential drug related problems [#192]	Veera Bobrova
	EL30	F	Factors associated with potentially inappropriate medications among elderly with Alzheimer's disease in the brazilian public health system [#196]	Luciane Cruz Lopes
	EL31	F	Drug-related problems among older ambulatory patients in Bulgaria – a pilot study [#205]	Maria Kamusheva
INTERVENTIONS/ IMPLEMENTATIONS	I11	F	Barriers and strategies to successful tuberculosis treatment in a high-burden tuberculosis setting: A qualitative study from the patient's perspective [#16]	Ivan Surya Pradipta
	I12	F	Development of a risk prediction tool for Clostridium difficile: A Scottish experience [#68]	Ansu Joseph A
	I13	F	Implementation research of medication reconciliation in hospital care: contributions of qualitative research to decision making [#175]	Lorena Rocha Ayres
	I14	F	Pharmacy-led implementation of evidence based medicine in primary care: Evaluating Diuretics in Usual Care study (EVIDENCE) [#177]	Angela Flynn
	I15	F	Valproate utilisation trends among women of child-bearing potential in Ireland between 2014 and 2017: a drug utilisation study using interrupted time series [#180]	John E Hughes
	I16	F	Implementation and effectiveness of an interprofessional support program for patients with type 2 diabetes in Swiss primary care settings [#182]	Noura Bawab
	I17	F	Medication use review at community pharmacies: an international pilot project [#188]	Anita Tuula
	I18	F	Deprescribing Protonpumpinhibitors in primary care: how often and how? [#190]	Catharina Schuiling-veninga
	I19	F	The survey of drug-drug interactions in kidney transplant patients [#200]	Istvan Horvath
MENTAL HEALTH	MH1	T	Utilization of antidepressants in Brazil: a study based on private and public consumption data [#36]	Claudia Garcia Serpa Osorio-de-Castro
	MH2	T	Systematic review of economic evaluations on the use of memantine alone or combined with donepezil for moderate to severe Alzheimer's disease [#37]	Claudia Garcia Serpa Osorio-de-Castro
	MH3	T	Cost-effectiveness analysis of memantine for severe Alzheimer's disease in Brazil [#38]	Claudia Garcia Serpa Osorio-de-Castro
	MH4	T	Morbi-mortality consequences of misuse of psychoactive prescription drugs in Portugal: a retrospective observational study - the MisuMedPT project [#103]	Ana Araujo
	MH5	T	Antidepressant treatment in children and adolescents: a descriptive cohort study [#122]	Livia Ruffolo

PATIENT VIEW	PV1	F	Measurement of Health Outcomes associated with National Level Medicines Usage in Ireland [#9]	Gary L. O'Brien
	PV2	F	The Burden of Medicines from the Patient Perspective: Validating the Living with Medicines Questionnaire v3 in a Swedish population [#32]	Joanne M. Fuller
	PV3	F	EUPRON - Nurses' practices in interprofessional pharmaceutical care in Europe. A cross-sectional survey in 17 countries [#53]	Elyne De Baetselier
	PV4	F	Trends in paracetamol use: a questionnaire pilot study [#66]	Irina Cazacu
	PV5	F	Knowledge, attitudes and practices of healthcare professionals towards adverse drug reaction reporting among public sector primary healthcare facilities in a South African district [#73]	Brian Godman
PATIENT VIEW	PV6	F	Bayesian Hierarchical Approaches for Multiple Outcomes in Routinely Collected Healthcare Data [#80]	Raymond Carragher
	PV7	F	Is it time to assign DDDs for oral antineoplastic drugs? Consumption of oral anticancer drugs in Norway compared by different units of measurements [#96]	Kristine Olsen
	PV8	F	Utilization of drugs for obstructive airway diseases in Hungary between 2008 and 2018 [#120]	Krisztina Schváb
	PV9	F	Cross regional comparison of proton pump inhibitors use in Portugal [#137]	Ana Araújo
	PV10	F	Capacity Building Electronic Survey in Pharmacoepidemiology and Drug Utilization for the Latin American Region [#146]	Maribel Salas
	PV11	F	A Modified Chronic Disease Score based on drug prescriptions recorded in the administrative databases [#158]	Marica Iommi
	PV12	F	Consumption of psychoactive medicines in disasters: A study in Minas Gerais, Brazil [#165]	Claudia Osorio-de-Castro
SAFETY + MISCELLANEOUS 1	SF1	T	Which medications are really associated with geriatric syndromes? A pharmacovigilance study [#7]	Marie-Laure Laroche
	SF2	T	Determining nationwide benzodiazepines prescribing pattern as a first step to guide rational pharmacotherapy [#46]	Katarina Gvozdanovic
	SF3	T	Adverse drug reactions in HIV-infected patients registered at four sentinel sites in South Africa [#71]	Brian Godman
	SF4	T	Gender differences in triptan utilization in Tuscany, Italy [#105]	Rosa Gini
	SF5	T	Mortal intracranial haemorrhages detection secondary to oral anticoagulants [#117]	Kristopher Amaro Hosey
	SF6	T	The indication and characteristics of proton pump inhibitor use [#130]	Zsófia Engi
	SF7	T	Characteristics of Epilepsy Therapy – A Questionnaire Based Study [#143]	Mária Matuz
	SF8	T	Off-label use of rituximab in patients with glomerulonephritis in a tertiary hospital [#162]	Carla Sans

SAFETY + MISCELLANEOUS 2	SF9	F	Role of clinical pharmacists in the risk assessment of healthcare associated infections (HAI) in a surgical unit [#178]	Edina Süli
	SF10	F	Norwegian stakeholders' definitions of medicines shortage [#187]	Ingunn Björnsdóttir
	SF11	F	Improving safety of drug administration for neonates [#194]	József Dénes Molnár
	SF12	F	Disposal of unused drugs around the world systematic review [#203]	Ana Tomas
	SF13	F	The Health Economic Analysis Of The Falsified Medicine Directive [#204]	Péter Vajda
	SF14	F	Analysis of antidepressant use in two Italian cities: a multidatabase pharmacoutilization study [#135]	Ippazio Cosimo Antonazzo

